ASSISTED REPRODUCTION
Birth outcomes of intended pregnancies among women who used assisted reproductive technology, ovulation stimulation, or no treatment Use of infertility treatments, such as assisted reproductive technology (ART) procedures and ovulation stimulation medications without ART, has increased dramatically in the United States. Assisted reproductive technology includes treatments in which both the oocyte and the sperm are handled in the laboratory. Medications to stimulate ovulation are used in ART procedures before retrieval of oocyte; however, these medications can also be used for non-ART treatments. From 1997-2000, the annual number of ART infants born increased by 44% (1) . In 2006, about 1% of all US births were to women who had undergone ART procedures (2) . Assisted reproductive technology use has been associated with an elevated risk of pregnancy complications for the mother and adverse outcomes for the infant, with the most common complication being multiple gestation (1) (2) (3) (4) (5) (6) . According to data from the US ART Surveillance System, 49% of 2006 ART births were multiple gestation births compared with only 3% multiple gestation for all US births (2, 7) . Infants born as multiples have an increased risk of preterm delivery, low birthweight, infant mortality, and longterm disability (8) (9) (10) .
In addition to problems associated with multiple gestation deliveries, studies have found that singleton ART-conceived infants are more likely to be low birthweight compared with singletons whose mothers did not use ART (11) (12) (13) (14) . Some studies have also found a greater risk of birth defects among singletons and multiples conceived using ART compared with those conceived without treatment (15) (16) (17) (18) ; however, the evidence is inconsistent and suggests that risk may be related to underlying infertility (19) (20) (21) . Concern about long-term sequelae of ART use, such as neurodevelopmental problems, has been identified as an area needing further research (22) (23) (24) (25) . Although research has been focused on the laboratory component of ART, the effect of ovulation stimulation medications alone has been less well studied. Birth outcomes among infants of mothers who used ovulation stimulation medications without ART is an important group to consider given that a recent study estimated that 4.6% of US infants born in 2005 were conceived as a result of non-ART ovulation stimulation (26) . In addition, there is some evidence that superovulation can affect DNA methylation, causing imprinting changes, which can effect fetal growth and development (27) .
The purpose of this study was to examine infant outcomes among women who reported using either ART or ovulation stimulation medications without around the time of conception using a large population-based sample. We used data from the Pregnancy Risk Assessment Monitoring System (PRAMS), which allowed us to investigate and control for multiple maternal characteristics, behaviors, and lifestyle factors, as well as differentiate ART and ovulation stimulation outcomes.
MATERIALS AND METHODS
PRAMS is a population-based surveillance system of maternal and infant health indicators funded in part by the Centers for Disease Control and Prevention and administered by state health departments. The unit of analysis for PRAMS is the woman who delivered a live birth. Mothers of twins and triplets are sampled once, and these women report on the health of one of their infants who is randomly selected at the time of sampling. The PRAMS does not sample women who give birth to multiples beyond triplets. The data are weighted for sample design, nonresponse, and noncoverage to represent all women who delivered a live birth in each participating PRAMS state for each calendar year. Details on the PRAMS methodology have been published previously (28) , and are available from the PRAMS web site http:// www.cdc.gov/prams. The Centers for Disease Control and Prevention Institutional Review Board approved the PRAMS protocol and all participating states approved the study plan.
We analyzed data from six states (Alabama, Illinois, Maine, Maryland, Nebraska, and Oklahoma) selected because they were the only PRAMS states to collect data on the use of both ART and ovulation stimulation medications from 2000-2003. We used 2000-2003 data for this analysis because these specific infertility measures were only available on the PRAMS survey during those years. Overall weighted response rates for each state were 70% or greater for each year of data. In the PRAMS questionnaire structure, only women who reported they were trying to become pregnant answered the questions on infertility treatment use. Therefore, our analysis was restricted to women who were attempting a pregnancy. In the absence of other fertility-related variables in the dataset (such as time to pregnancy), this subgroup of women constituted an appropriate population to study differences between birth outcomes of women who used infertility treatments and those who did not.
The PRAMS dataset included variables linked from the birth certificate (1989 standard birth certificate) and variables from the questionnaire. We obtained information on maternal age, race, ethnicity, education level, marital status, parity, plurality, infant gestational age, birthweight, and other medical risk factors (identified by a dichotomous indicator) from the birth certificate. We used PRAMS questionnaire data on maternal prepregnancy height and weight, multivitamin use, and smoking and alcohol consumption during the third trimester of pregnancy. The dependent variable in the analysis was birth outcome (birthweight, gestational age, small for gestational age (SGA), length of infant hospital stay after birth, admission to the neonatal intensive care unit (NICU), and infant death (between the time of the live birth and survey response). One percent or less of the data for the outcome variables was missing, with the exception of birthweight (<4%). SUDAAN software was used for the analysis to account for PRAMS' complex sampling design and statistical weighting (29) . More detail on the study methods can be found in Supplemental Table 1 .
There were 35,848 respondents in the dataset representing 1,351,718 women who delivered a live infant in six states during 2000-2003; 16,748 reported they were trying to get pregnant with their new baby and were included in the analysis. There were 251 women (1.5%) with missing information on use of infertility treatment who were excluded from the analysis. Among the remaining 16,497 women, 15,406 gave birth to singleton infants, 980 to twins, and 111 to triplets. We did not examine differences in birth outcomes among triplet infants separately because of small numbers; however, mothers of triplet infants are included in the prevalence estimates in Table 1 .
RESULTS
Overall, 1,824 (10.9%) women who were trying to become pregnant reported using infertility treatment. There were 920 (5.5%) women who reported using ART, 904 (5.4%) women who reported use of ovulation stimulation medications alone, and 14,673 (87.6%) women who reported no infertility treatment.
There were significant differences by infertility treatment status for the following maternal characteristics: age, race, ethnicity, marital status, education, parity, income, multivitamin use before pregnancy, cigarette smoking in the last trimester of pregnancy, and prepregnancy body mass index (BMI). There were no differences in alcohol consumption during pregnancy or birth interval (among multiparous women) ( Table 1) .
Infant Outcomes
The prevalence of adverse infant outcomes increased with the use of more intensive treatment. Women using ART were at the highest risk and those not using any treatment were at the lowest risk. This pattern is evident not only in the overall sample (Table 1) , but also when restricted to singleton infants (Table 2) . Among singleton infants, there was a significant difference in the prevalence of low birthweight (very low birthweight and low birthweight combined was 9.8% of the ART group, 6.5% for the medication-only group, and 5.1% for the no treatment group). Preterm birth (<37 weeks gestation) was also highest among the ART group (16.1%), followed by the medication-only group (11.0%), and lowest in the no treatment group (8.0%). The pattern is similar for SGA, infant hospital stay longer than 5 days, and infant spending time in the NICU, although long hospital stay and NICU admission were not statistically significant ( Table 2 ). All of the affected infants in the study had more than one study outcome. 
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were also significantly more likely to spend 5 or more days in the hospital (cOR: 1.49, CI: 1.04, 2.14), and more likely to be admitted to the NICU (cOR: 1.53, CI: 1.12, 2.24). There was no significant difference in very low birthweight or infant death (Table 3) .
In the adjusted analysis, we looked among singletons only at outcomes that were significant in the unadjusted analysis described previously. Women who used ART were more than two times as likely to have a low birthweight singleton infant (adjusted OR [AOR]: 2.20, CI: 1.55, 3.13). ART use was also associated with preterm birth (AOR: 1.91, CI 1.31, 2.80) and delivering an SGA infant (AOR: 1.98, CI: 1.21, 3.24) ( Table 3 ). For hospital stay of 5 days or more, there were interactions with parity, age, and BMI. Further analysis showed no significant association for primiparous women. Only the relationship among multiparous young women with low or normal BMI was significant; however, the estimate is imprecise (AOR: 9.30, CI: 3.18, 27.19) ( Table 4 ). For admission to the NICU, we found interactions with parity and age. Again, there was no association for primiparous women. However, for multiparous young women, we found an association between ART use and NICU admission with an imprecise estimate (AOR: 7.16, CI: 3.23, 15.87) ( Table 4) .
Comparing mothers of singleton infants who used ovulation stimulation medications without ART to women who received no treatment, those who used ovulation stimulation medications alone were significantly more likely to have an SGA infant (cOR: 1.59, CI: 1.11, 2.27) than women who received no treatment. In the adjusted analysis, this association remained significant (AOR: 1.71, CI: 1.09, 2.69) ( Table 3) .
Among twin births, there were no significant differences in any of the infant outcomes that we examined when comparing ART users with women who received no treatment. Nor did we find any significant differences in twin outcomes comparing women who used ovulation stimulation medications without ART with women who received no treatment. However, many of the effect sizes were large among the medication-only group, possibly indicating a relationship, but inconclusive due to the small sample size (data not shown).
DISCUSSION
Overall, 10.9% of the women in our study used infertility treatment. This is higher than other reports because our study was restricted to women who were trying to become pregnant, rather than the entire birth population (2). We confirmed the previously reported relationship that singleton infants born to mothers who undergo ART procedures are more likely to be low birthweight (11) (12) (13) (14) (15) , preterm (13, 14, 30) , or SGA (13, 30, 31) than singleton infants born to mothers who did not undergo treatment. We further provide one of a few studies of this size and diversity showing an association between the use of ovulation stimulation medications without ART and infants being born small for gestational age for singleton infants. Although the literature on twin outcomes is inconsistent, our study using a large population-based sample corroborates the findings of a number of studies that do not note any difference among outcomes of twin infants born after ART compared with spontaneously conceived twins (11, 30, 32) . Our findings relative to ovulation stimulation-only twins were inconclusive.
Our findings suggest a relationship between ART use and the risk of an infant's hospital stay of 5 or more day and NICU admission for multiparous women less than 35 years of age. Other studies have found increased NICU admission for singleton ART births, and longer hospitalizations for ART infants (33, 34, 36) , but not specific to younger women. There is some evidence that increased maternal morbidity and infant low birthweight linked with ART use may be associated with poor gamete quality, or other factors related to the maternal or paternal subfertility rather than the ART procedures. The research in this area is inconclusive and the exact mechanism responsible for the difference in infant outcomes has not been identified (13, 21, 35, 37, 38) . Although the confidence intervals around our estimates for these indicators are wide, the findings may suggest that the cause of underlying infertility is playing a role in the increased use of hospital services among some ART singleton infants. These younger, multiparous women may be more likely to have an underlying cause of infertility that could affect fetal growth or development.
We found that mothers who reported using ovulation stimulation medications without ART were more likely to have an infant that was small for gestational age compared with infants who were conceived without treatment. Other studies have also linked ovulation stimulation with adverse infant outcomes such as prematurity and low birthweight, but not specifically SGA (35, 36) . There are several limitations to this study. Although we controlled for state of residence in our regression analysis, the data are from six states selected based on their use of the PRAMS questions on infertility, and findings are not generalizable to other states or the entire United States. The PRAMS data on use of ART and ovulation stimulation medications are self reported in the postpartum period. A validation study by Schieve et al in 2006 (39) found that using the infertility questions from 2000-2003, PRAMS overestimates the number of ART births when compared with estimates from the US ART Surveillance System suggesting that women might be reporting past use of treatments. We do not have information on the treatment used, on the underlying cause of infertility, or on other potentially confounding factors such as gamete quality. And, although the questions refer to the most recent pregnancy, we do not know whether the procedures or medications directly resulted in the pregnancy with the infant about whom the woman is being surveyed.
Despite these limitations, PRAMS provides a large populationbased sample that enables examination of multiple infant outcomes, and an appropriate comparison group of other women who reported they were actively trying to get pregnant, which is more similar to those women who use ART than the population of all women delivering a live birth. The availability of multiple covariates from the PRAMS survey allows for the use of robust approaches to identify and control for possible confounding variables.
The use of infertility treatments has become increasingly common in the United States, and risks go beyond multifetal pregnancies. The findings from this study add to the growing body of literature on the use of infertility treatments and the safety of these treatments for the infants that are conceived. Considering the elevated risks, especially for singleton births from ART and ovulation stimulation medications alone, couples who are considering treatment should be counseled on potential risks to their singleton infants, in addition to the increased risk of having a multiple birth as the result of ART or ovulation stimulation medications. 
